Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.73 +3.01%

+$0.81 today

Market cap
$1.81B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 5.16M

Average 1.81M

RARE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ultragenyx Pharmaceutical Inc.NASDAQ: RARE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 77.9%

Gross margin was 77.9% in Q1 FY2026, down 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 83.6%, down 1.6 pp year over year. Over 3 fiscal years it narrowed by 8.4 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
77.9%-8.0 pp QoQ
Last fiscal yearDec 2025
83.8%-2.5 pp YoY
LTMMar 2026
83.6%-1.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.5 pp——
1 year-2.5 pp——
3 years-8.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
83.8%
Year-over-year change
-2.5pp

Gross Margin vs competitors

How RARE compares with its peers on the latest reported figures

  • RARE's LTM Mar 2026 gross margin of 83.6% is the 3rd highest of the 10 companies compared; the peer median is 74.1%.
  • Its year-over-year change of -1.6 pp is the 5th highest of 8, against a peer median of -1.4 pp.
  • Over three fiscal years its change of -8.4 pp compares with a peer median of +1.7 pp.
RARE Competitors Peer median
Gross Margin for RARE and competitors
Company Period LTM level YoY 3-year change
BBIOBridgeBio Pharma, Inc.LTM Jun 202693.3% -2.8 pp-1.2 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 202679.9% -1.4 pp+1.1 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
MREOMereo BioPharma Group plcLTM Mar 2026-105.7% ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding RARE) 74.1%-1.4 pp+1.7 pp

Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.41M363.33M434.25M560.23M673M
Cost of Revenue16.01M28.32M45.21M76.73M109M
Gross Profit335.4M335.01M389.04M483.5M564M
Gross Margin95.4%92.2%89.6%86.3%83.8%
Research & Development497.15M705.79M648.45M697.87M750M
Selling, General & Admin219.98M278.14M309.8M321.61M349M
Operating Expenses717.14M983.93M958.25M1.02B1.1B
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
EBITDA(410.32M)(640.49M)(516.45M)(469M)(474M)
EBITDA Margin-116.8%-176.3%-118.9%-83.7%-70.4%
Operating Income(381.74M)(648.92M)(569.21M)(535.97M)(535M)
Operating Margin-108.6%-178.6%-131.1%-95.7%-79.5%
Interest Income1.93M11.07M26.69M36.51M25M
Interest Expense29.42M43.02M66M63.04M62M
Other Income / Expenses(71.24M)(52.81M)(39.26M)(31.61M)(36M)
Income Before Tax(452.98M)(701.73M)(608.46M)(567.59M)(571M)
Pre-Tax Margin-128.9%-193.1%-140.1%-101.3%-84.8%
Income Tax Expense1.04M5.7M(1.83M)1.6M4M
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Net Margin-129.2%-194.7%-139.7%-101.6%-85.4%
EPS (Basic)(6.70)(10.12)(8.25)(6.29)(5.83)
EPS (Diluted)(6.70)(10.12)(8.25)(6.29)(5.83)
Weighted Avg Shares67.8M69.91M73.54M90.54M98.6M
Weighted Avg Shares (Diluted)67.8M69.91M73.54M90.54M98.6M

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.